UBS Group’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

UBS Group’s Portfolio BSX.PRA Stock Details BSX.PRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-375	Closed	-$45.4K	–	10310
2023 Q1	$45.4K	Sell	375 -42	-10%	-$4.83K	﹤0.01%	6529
2022 Q4	$47.9K	Sell	417 -502	-55%	-$55.3K	﹤0.01%	6818
2022 Q3	$93K	Buy	919 +426	+86%	+$45.1K	﹤0.01%	5770
2022 Q2	$50K	Sell	493 -253	-34%	-$27.6K	﹤0.01%	5919
2022 Q1	$87K	Buy	+746	New	+$86.3K	﹤0.01%	6023

Other funds holding BSX.PRA

LTI

Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

UBS Group's BSX.PRA Position: Q2 2023 in Review

UBS Group sold out of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) in Q2 2023, closing a stake of 375 shares — an estimated $45.4K sold.

UBS Group first reported a position in BSX.PRA in Q1 2022 and held it in 5 quarters. The position peaked at $93K in Q3 2022. 1 fund tracked by Wall St. Rank holds BSX.PRA as of Q2 2023.

UBS Group reported no remaining Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position as of Q2 2023 after selling out during the quarter.
UBS Group sold 375 Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A shares in Q2 2023, an estimated $45.4K.
UBS Group first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q1 2022 and held it in 5 quarters.
UBS Group's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $93K in Q3 2022.
1 fund tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.